DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Aktueller Standort:
> This Story

Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment



Molecular Imaging Homepage

Canada forms council for radioisotope production Seeks to raise awareness about importance of medical isotope production to the public

NVIDIA aims to bring AI insights to existing global fleet of imaging systems With Project Clara, older scanners may gain remote access to latest capabilities

Imaging innovation yields new insights into cardiac health As ultrasound analytics increase, other cardiac imaging tools become more accurate and affordable

Researchers develop PET tracer that may predict effectiveness of depression treatment Could be used for other mental disorders

New PET imaging agent may help guide treatment for neurodegenerative diseases Preclinical study generates favorable results

MGH researchers develop AI technique for fast, high-quality imaging scans Image reconstruction in a fraction of a second

CereMetrix Silver neuroimaging analytics platform scores FDA approval Quantifies brain function down to the voxel level

New PET imaging agent predicts tumor response to lung cancer drug Could lead to better patient management and outcomes

PET beats SPECT for detecting coronary artery disease: study Detected 79 percent of severe obstructive cases versus 70 percent

PET/MR and the future of pediatric chemotherapy Dr. Ashok Joseph Theruvath, postdoctoral research fellow in the Molecular Imaging Program at the Stanford School of Medicine discusses promising research for assessing pediatric chemo outcomes

Building One of Shine's medical
isotope production campus is complete

SHINE completes Building One of medical isotope production facility

by John R. Fischer , Staff Reporter
SHINE Medical Technologies Inc. (SHINE) has completed construction on and begun occupying the first building of its medical isotope production campus in Janesville, Wisconsin.

The completion of Building One moves the Wisconsin-based enterprise one step closer to being the first domestic source in the U.S. for the production of molybdenum-99 (Mo-99) which, along with other radioisotopes produced there, will go toward the detection and treatment of various diseases, such as heart disease and cancer.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

"The fact that SHINE is building new moly-99 production and processing infrastructure means we will have the most reliable supply of moly-99 in the world," Katrina Pitas, vice president for business development at SHINE, told HCB News. "Because we don’t use a reactor, SHINE’s process creates dramatically less nuclear waste than any process that does, and creates moly-99 that is 10,000 times more concentrated than moly-99 produced by typical accelerator processes."

The completion of Building One follows the FDA’s clearance of NorthStar’s RadioGenix System for the production of Mo-99, pushing the two enterprises further in their competition to bring a domestic, non-uranium-based source of Mo-99 to the U.S.

Building One, designed as a private, nuclear technology facility, will be the location for employee training and the development of operating history with equipment while the main SHINE production facility is under construction. It eventually will become a technology development center.

The country, which has lacked such a source for more than 25 years, currently relies on shipments of the radioisotope from other countries, placing it at risk of shortages and supply chain issues. All Mo-99 currently utilized is derived from enriched uranium, posing risks to the environment.

"SHINE's approach is the best because it’s safer, cleaner, lower cost, and more reliable than other methods," said Pitas. "It doesn't require a 50+-year-old, highly-enriched-uranium-fueled nuclear reactor, and produces moly-99 that fits into the existing moly-99 supply chain."

JP Cullen oversaw construction, finishing the six month project three weeks ahead of schedule with zero OSHA-recordable incidents and on budget.

Buildout of the inside the 11,400 sq. ft. building is beginning now, with the facility set to house the first integrated, full-size SHINE production system this summer.

The U.S. Nuclear Regulatory Commission awarded SHINE a construction permit for the facility in 2016.

Once the facility is operational, customers, such as GE Healthcare and Lantheus Medical Imaging, will have to submit a supplemental NDA to the FDA to update their current clearance for utilizing Mo-99 produced by SHINE in their Tc-99m generators.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Alle Gesundheitsdienstleister-Tools anzeigen
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.